(Q37977414)

26 August 2017

title

Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls (English)

1 reference

26 August 2017

1 reference

3

Lucas Minig

1 reference

26 August 2017

Iván Díaz-Padilla

1

1 reference

26 August 2017

Albiruni Ryan Abdul Razak

series ordinal

2

1 reference

26 August 2017

Marcus Q Bernardini

series ordinal

4

1 reference

26 August 2017

Josep María Del Campo

series ordinal

5

1 reference

26 August 2017

publication date

1 January 2012

1 reference

Clinical and Translational Oncology

26 August 2017

published in

1 reference

26 August 2017

volume

14

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

15-20

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-012-0756-8

26 August 2017

exact match

0 references

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

CA-125 levels in predicting optimal cytoreductive surgery in patients with advanced epithelial ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Significance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Quality of care in advanced ovarian cancer: the importance of provider specialty

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Prognostic factors for complete debulking in first- and second-line ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

CA125 Nadir values as a prognostic factor in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0756-8

Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer

21 January 2018

1 reference

12 December 2020

CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study

1 reference

12 December 2020

Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer

1 reference

12 December 2020

Pretreatment CA-125 and risk of relapse in advanced ovarian cancer

1 reference

12 December 2020

The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer

1 reference

12 December 2020

CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: A population-based study

1 reference

12 December 2020

Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer

1 reference

12 December 2020

Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer

1 reference

12 December 2020

Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study

1 reference

12 December 2020

Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?

1 reference

12 December 2020

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy

1 reference

12 December 2020

A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma

1 reference

12 December 2020

The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125

1 reference

12 December 2020

Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer

1 reference

12 December 2020

Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study

1 reference

12 December 2020

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

1 reference

12 December 2020

Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer

1 reference

12 December 2020

New tumor markers: CA125 and beyond.

1 reference

12 December 2020

10.1007/S12094-012-0756-8

Identifiers

DOI

1 reference

26 August 2017

1 reference